Is Aethlon Medical a Good Healthtech Company to Own?

NASDAQ: AEMD | Aethlon Medical, Inc. News, Ratings, and Charts

AEMD – Therapeutic technology company Aethlon Medical (AEMD) has been making several positive developments, but its losses widened in the second quarter. So, let’s find out if it is wise to bet on the stock now.

Medical devices technology company Aethlon Medical, Inc. (AEMD) is known for its Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. After the recent success of the Hemopurifier demonstration, clinical researchers have expressed interest in joining their ongoing clinical trial investigation to treat patients with SARS-CoV-2/COVID-19 infection.

However, the stock has lost 24% over the past three months. In addition, it is currently trading 69% below its 52-week high of $12.49, which it hit on June 9, 2021, due to the Reddit-fueled short squeeze. Moreover, AEMD’s losses widened in the second quarter. So, AEMD’s near-term prospects look bleak.

Here’s what could influence AEMD’s performance in the upcoming months:

Top Line Growth Doesn’t Translate into Bottom Line Improvement

For the fiscal first quarter ended June 30, 2021, AMED’s government contract revenue came in at $131,966. The company’s total assets increased 142.4% sequentially to $25.87 million. However, its operating loss for the quarter increased 48.8% year-over-year to $2.10 million. In comparison, its net loss came in at $2.10 million, representing a 48.7% year-over-year increase. Its loss per share came in at $0.16 compared to $0.15 in the prior-year period.

Selling Shares to Fund Growth Activities

On June 10, 2021, AEMD entered into a definitive agreement with a single institutional investor to sell roughly 1 million shares of its common stock. It is expected to use the net proceeds for working capital and other general corporate purposes. However, this could lead to share dilution.

Stretched Valuation

In terms of forward P/S, AEMD’s 52.69x is 585.3% higher than the industry average of 7.69x. Likewise, its forward EV/S of 31.34x is 351.9% higher than the industry average of 6.93x.

POWR Ratings Reflect Bleak Prospects

AEMD has an overall rating of D, which equates to Sell in our POWR Ratings system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree. 

Our proprietary rating system also evaluates each stock based on eight different categories. AEMD has a D grade for Quality. This is justified given its 0.04% trailing-12-month asset turnover ratio, 89.6% below the industry average of 0.36%.

AEMD has a D grade for Value, in sync with its higher-than-industry valuation ratios. Also, the stock has an F grade for Stability.

In addition to the POWR Rating grades I’ve just highlighted, we’ve also rated AEMD for Growth, Sentiment, and Momentum. Click here to get all the AEMD ratings.

Moreover, of the 179 stocks in the Medical – Devices & Equipment industry, AEMD is ranked #161.

Bottom Line

AEMD is one of the emerging companies focused on developing products to diagnose and treat life and organ-threatening diseases. However, the company released disappointing earnings results in the first quarter. Moreover, analysts expect its EPS to remain negative in the upcoming quarters. So, as the stock looks overvalued at the current price level, it is best avoided now.

How Does Aethlon Medical (AEMD) Stack Up Against its Peers?

While AEMD has an overall POWR Rating of D, you might want to consider investing in the following Medical – Devices & Equipment stocks with an A (Strong Buy) rating: Utah Medical Products, Inc. (UTMD), Natus Medical Incorporated (NTUS), and HOYA Corporation (HOCPY).

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


AEMD shares were trading at $3.86 per share on Wednesday afternoon, down $0.37 (-8.75%). Year-to-date, AEMD has gained 56.28%, versus a 17.34% rise in the benchmark S&P 500 index during the same period.


About the Author: Nimesh Jaiswal


Nimesh Jaiswal's fervent interest in analyzing and interpreting financial data led him to a career as a financial analyst and journalist. The importance of financial statements in driving a stock’s price is the key approach that he follows while advising investors in his articles. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
AEMDGet RatingGet RatingGet Rating
UTMDGet RatingGet RatingGet Rating
NTUSGet RatingGet RatingGet Rating
HOCPYGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


How Much Resistance @ 6,000 for Stocks?

The post-election rally was an exciting burst for the stock market. With that the S&P 500 (SPY) made new highs just above 6,000. Since then stocks have struggled begging the question: what happens next? 44 year investing veteran Steve Reitmeister provides the answers along with his top 11 stocks to buy now.

3 Streaming Stocks Benefiting from Cord-Cutting Trends

As streaming continues to dominate the digital entertainment landscape, the global streaming market presents a lucrative investment opportunity. So, it could be ideal to invest in fundamentally solid streaming stocks Netflix (NFLX), Walt Disney (DIS), and Roku (ROKU). Read further...

3 Gold Stocks to Buy as Safe-Haven Demand Grows

Gold is a stable investment now due to its role as a safe-haven asset during economic uncertainty, rising demand, industrial use, and growth, bolstered by central bank purchases and interest rate cuts. Therefore, investors should consider investing in top gold stocks such as Newmont (NEM), Barrick Gold (GOLD), and Agnico Eagle Mines (AEM). Read more...

3 AI Stocks Transforming Industries and Driving Future Growth

With rapid digitalization, rapid adoption, and development, as well as surging demand, the AI market is on the rise. Amid this backdrop, investors could buy fundamentally solid AI stocks NVIDIA Corporation (NVDA), Microsoft (MSFT), and Meta Platforms (META) poised for substantial gains. Continue reading...

Does Trump Change Stock Market Outlook?

The rally of the S&P 500 (SPY) after the election gives a sense that investors are happy that Trump was elected. But perhaps there is more to this story than meets the eye. That’s why Steve Reitmeister shares his updated market outlook taking into account the pros and cons of Trumps proposed new policies. This comes with a preview of his top 11 stocks to buy now.

Read More Stories

More Aethlon Medical, Inc. (AEMD) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All AEMD News